Bioluminescence Ventures Emerges from Stealth with $477M AUM - Business Wire

Bioluminescence Ventures has officially emerged from stealth mode, announcing $477 million in assets under management. The venture firm goes public with a significant fund size, signaling its readiness to actively invest in its target sectors.

11/1/2023

Therapeutics Company Octant Secures $80 Million In Series B Funding - Pulse 2.0

Octant, a therapeutics company, has successfully raised $80 million in Series B funding, marking a significant milestone in its growth and drug development efforts.

4/27/2022

Wilson Sonsini Advises Octant on $80 Million Series B and Partnership with Bristol Myers Squibb - Wilson Sonsini

Wilson Sonsini advised Octant on its $80 million Series B financing and a strategic partnership with Bristol Myers Squibb, supporting the biotech company's growth and drug discovery initiatives.

4/22/2022

Octant sets sail for new era of drug discovery with $80M funding, Bristol Myers partnership - Fierce Biotech

Octant has secured $80M in funding and formed a partnership with Bristol Myers Squibb to advance its next-generation drug discovery platform into a new era of biopharmaceutical development.

4/21/2022

Who is Chris Dixon? - Fortune

An overview of Chris Dixon, a prominent venture capitalist and general partner at Andreessen Horowitz (a16z), known for his influential role in crypto and Web3 investments.

4/21/2022

Octant Scores $80M in Series B Funds, Partnership with BMS - BioSpace

Octant has secured $80 million in Series B funding and announced a strategic partnership with Bristol Myers Squibb (BMS), marking a significant milestone for the biotech company.

4/21/2022

Catalio Capital Management Leads $80M Series B in Octant - citybiz

Catalio Capital Management has led an $80 million Series B funding round in Octant, a biotech company. This significant investment highlights growing interest in the biotechnology sector and Octant's potential in drug discovery and development.

4/21/2022

BMS joins Octant’s $80M financing and signs on as a drug discovery partner - MedCity News

Bristol Myers Squibb (BMS) has joined Octant's $80M financing round and established a drug discovery partnership with the biotech company.

4/21/2022

The VC who helped spin up Andreessen Horowitz's bio fund just raised $50 million for a third solo fund - Business Insider

A venture capitalist who played a key role in launching Andreessen Horowitz's bio fund has successfully raised $50 million for their third independent fund, marking continued growth in solo VC activity.

6/3/2021

Biotech's top 10 money raisers of 2020 - Fierce Biotech

Fierce Biotech highlights the top 10 biotech companies that raised the most funding in 2020, showcasing the year's biggest financial achievements in the biotechnology sector.

3/22/2021

Genentech taps Stanford University spinout for AI drug discovery partnership - Fierce Biotech

Genentech has partnered with a Stanford University spinout company to advance AI-driven drug discovery, combining cutting-edge artificial intelligence with biopharmaceutical expertise.

10/19/2020

Embracing the Intersections of Innovation: Our Investment in Nautilus Biotechnology - Madrona

Madrona announces its investment in Nautilus Biotechnology, a company at the intersection of innovation in life sciences and technology, highlighting the firm's commitment to groundbreaking biotech ventures.

5/20/2020

Venture-Capital Investors Share Their Healthcare Predictions for 2020 - Business Insider

Venture-capital investors share their key predictions for the healthcare industry in 2020, highlighting emerging trends and investment opportunities in the sector.

12/19/2019

Dog cancer treatment startup raises $5 million from Andreessen Horowitz and others - TechCrunch

A startup focused on cancer treatment for dogs has raised $5 million in funding from prominent investors including Andreessen Horowitz, aiming to advance veterinary oncology solutions.

1/23/2019

TwoXAR announces Series A in quest to collapse drug discovery timelines - MIT Sloan

TwoXAR, an AI-driven drug discovery company, announced its Series A funding round aimed at significantly reducing the time required to discover and develop new drugs using artificial intelligence.

3/21/2018

Artificial intelligence firm twoXAR raises $10M for partnering drive - Fierce Biotech

AI-driven drug discovery company twoXAR has raised $10 million to accelerate its partnering strategy, aiming to collaborate with pharmaceutical companies to advance drug candidates.

3/19/2018

twoXAR Raises $10M in Series A Financing - FinSMEs

twoXAR has successfully raised $10 million in a Series A financing round, marking a significant milestone for the company as it advances its operations and growth strategy.

3/19/2018

Andreessen Horowitz Is Digging Deeper Into Biotech - BuzzFeed News

Venture capital firm Andreessen Horowitz is expanding its presence in the biotech sector, signaling a deeper commitment to life sciences and biotechnology investments.

6/21/2017

Emerging Pharma Leaders: Andrew A. Radin and Andrew M. Radin - Pharmaceutical Executive

Pharmaceutical Executive highlights Andrew A. Radin and Andrew M. Radin as emerging leaders in the pharmaceutical industry, recognizing their notable contributions and potential impact on the sector.

10/3/2016

Andreessen Horowitz Invests in Freenome Through New Bio Fund - Business Insider

Andreessen Horowitz has invested in Freenome through its newly established bio-focused fund, signaling the firm's growing interest in the biotechnology and life sciences sector.

6/9/2016